[Federal Register Volume 62, Number 239 (Friday, December 12, 1997)]
[Notices]
[Page 65433]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-32469]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Promotion of Homologous
Recombination DNA Pairing by RecA And RecA Peptides
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice is accordance with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(I) that the National Institutes of Health (NIH), Department
of Health and Human Services, is contemplating the grant of an
exclusive world-wide license to practice the inventions embodied in
U.S. Patents No. 5,460,941, entitled, ``Method of Targeting DNA'' and
5,510,473, entitled, ``Cloning of the RecA Gene From Thermus Aquaticus
YT-1'', U.S. Patent Applications Serial Numbers 08/446,413, entitled,
``Cloning of the RecA Gene From Thermus Aquaticus YT-1'', 08/483,115
entitled, ``Promotion of Homologous Recombination DNA Pairing By Rec-A-
Derived Peptides'', 60/001,384 and 08/682,305, ``Rec A Assisted Cloning
of DNA'', and corresponding U.S. and foreign patent applications to the
Pangene Corporation of Menlo Park, California. The patent rights in
these inventions have been assigned to the United States of America.
DATES: Only written comments and/or applications for a license which
are received by NIH on or before February 10, 1998 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments and other materials relating to the contemplated licenses
should be directed to: Raphe Kantor, Ph.D., Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A
signed Confidentially Agreement will be required to receive copies of
the patent applications.
SUPPLEMENTARY INFORMATION: This technology covers methodology for
inducing sequence-specific homologous recombination between an
exogenous DNA sequence and the corresponding genomic DNA sequence by
use of the E. coli RecA protein. The RecA protein brings together an
exogenous DNA sequence and a corresponding genomic DNA sequences for
homologous recombination. A peptide of RecA can be substituted for the
entire E. Coli RecA protein to target a double-strand of DNA or to
inhibit transcription of a given gene. The ability of a RecA peptide to
induce homologous recombination gives this technology broad commercial
applicability. The peptide can be used in site-specific targeting of
DNA sequences for purposes of cleavage, protection or enrichment as a
research reagent, a diagnostic tool or for use in gene therapy.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
The field of use of this exclusive license may be limited to human
therapeutics.
Applications for a license filed in response to this notice will be
treated as objections to the grant of the contemplated licenses.
Comments and objections submitted to this notice will not be available
for public inspection and, to the extent permitted by law, will not be
released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: December 1, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-32469 Filed 12-11-97; 8:45 am]
BILLING CODE 4140-01-M
